Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2013

View Archived Issues

Novartis prepares new protein kinase inhibitors

Initial results available from phase I/II study of indibulin in metastatic breast cancer

Iron chelator ameliorates experimental Alzheimer's disease

French scientists design novel DCL enzyme inhibitors

Merck & Co. presents new mGlu2 receptor agonists

U.S. scientists divulge novel cytochrome P450 1A2 inducers

Metabolex presents new GPBA receptor agonists

Novel compounds for autoimmune disorders patented

Ultragenyx inlicenses triheptanoin from Baylor Research Institute

BIKAM Pharmaceuticals prepares new opsin-2 ligands

Esperion's ETC-1002 lowers LDL cholesterol in phase II trial

GeoVax completes enrollment in phase I/II trial for HIV/AIDS vaccine

Dosing completed in phase III BromSite study

Phase II trial of NeoFuse stem cell product meets endpoints

Novel drug-eluting bioadhesive gel reduces inflammation in atherosclerotic plaques in vivo

Morphotek discloses results from phase III study in platinum-sensitive epithelial ovarian cancer

KaloBios begins phase II study of Humaneered PEGylated monoclonal antibody fragment

Topline data reported from phase II study of tivantinib in colorectal cancer

MSD suspends availability of Tredaptive

Evotec advances compound into preclinical development under collaboration with Ono

Mirabegron approved in Europe

European Commission approves use of Zytiga earlier in the treatment cycle

Biota synthesizes promising inhibitor of cell division protein FtsZ

FDA grants orphan drug designation to Telik's investigational treatment for MDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...